Developer docs
API playgroundTry for free, no card

Search company profiles

HanAll Biopharma

Full company profile

uuid0007duy

Namestring
HanAll Biopharma
Legal namestring
HanAll Biopharma Co., Ltd.
Websiteurl
hanall.com
Company typeenum
Public
Founded yearint
1973
Descriptiontext

HanAll Biopharma Co., Ltd. (KRX: 009420.KS) is a Seoul-headquartered, publicly listed biopharmaceutical company founded in 1973 that develops innovative biologic medicines across ophthalmology, immunology, oncology, and neurology. Its pipeline is anchored by batoclimab (HL161) and the next-generation HL161ANS (IMVT-1402), both fully human subcutaneous antibodies targeting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG in autoimmune diseases including myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease; HL161ANS is licensed to Immunovant for the US and Europe and is designed to minimize albumin and LDL perturbation. Tanfanercept (HL036) is a molecularly engineered topical TNFR1 fragment for dry eye disease, currently in the Phase 3 VELOS-4 study with Daewoong Pharmaceutical. HL192 (ATH-399A) is a Nurr1 activator co-developed with Daewoong and NurrOn Pharmaceuticals as a potential disease-modifying therapy for Parkinson's disease, having completed a 76-participant Phase 1 first-in-human study in 2024. HanAll also holds an exclusive license to Turn Biotechnologies' Epigenetic Reprogramming of Aging (ERATM) mRNA technology for ophthalmic and otic indications, with potential deal value exceeding US$300 million for the initial product, and is co-developing immuno-oncology assets HL187 (anti-TIGIT) and HL186 (anti-TIM-3) with Daewoong.

The company's revenue model combines direct sales of an established Korean pharmaceutical portfolio in endocrine, circulatory, and urologic therapeutic areas (133 billion KRW in 2025, 13% YoY growth, three consecutive years of double-digit growth) with licensing, milestone, and co-development receipts from global partners including Immunovant, Daewoong, NurrOn, and Turn Biotechnologies. Distribution is via traditional pharmaceutical channels in Korea and through licensed partners internationally; the company maintains offices in Seoul, Rockville (MD, USA), Osaka (Japan), and Indonesia. Revenue economics are increasingly tied to clinical and regulatory milestones across the FcRn franchise and the maturing ophthalmology and neurology programs, offset by an active cost base — operating profit was -0.9 billion KRW in 2025 and net income -5.6 billion KRW versus +3.5 billion KRW in 2023, reflecting elevated SG&A and R&D investment (over 10% of annual revenue).

Customer concentration is bimodal: a distributed base of Korean wholesalers, hospitals, and pharmacies absorbs the legacy pharmaceutical volume, while a small set of global licensing partners — principally Immunovant for US/European FcRn rights and Daewoong for co-developed assets — governs the long-term value realization of the pipeline. This concentration was sharpened by the termination of the Harbour BioMed Greater China license in March 2025 and by Immunovant's April 2026 Phase 3 failure of batoclimab in thyroid eye disease, both of which crystallize near-term execution risk on the company's most strategic licensing relationship.

Short descriptiontext

HanAll Biopharma (KRX: 009420.KS) is a Seoul-based, publicly listed biopharmaceutical company developing FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF (tanfanercept), a Nurr1 activator (HL192) and licensed epigenetic reprogramming technology, licensed globally via Immunovant, Daewoong, NurrOn and Turn Bio, alongside a Korean specialty pharma portfolio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical development, anti-FcRn antibodies, autoimmune disease therapeutics, immuno-oncology pipeline, topical ophthalmology drugs
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeHardware Sales
Description

Sales of established pharmaceutical products including probiotics, hair loss treatments, and urology medications. Generated 133 billion KRW in pharmaceutical sales in 2025 with 13% year-over-year growth, marking three consecutive years of double-digit growth.

hanall.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing agreements including upfront payments, development milestones, and royalties from partners such as Immunovant for US/Europe and Harbour BioMed for China.

hanall.com
3Co-development and Collaboration Revenue
TypeLicensing Royalties
Description

Revenue from co-development partnerships including milestone achievements from collaborations with Daewoong Pharmaceutical, NurrOn Pharmaceuticals, and other partners.

hanall.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HanAll Biopharma is a global biopharmaceutical company that develops, manufactures, and commercializes innovative biologic therapies across four therapeutic areas — Ophthalmology, Immunology, Oncology, and Neurology. The company's commercial portfolio spans established prescription drugs (probiotics, hair loss, and urology medications) in Korean and Asian markets, while its R&D pipeline includes anti-FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF for dry eye disease (tanfanercept), a Nurr1 activator for Parkinson's (HL192), and immuno-oncology candidates (HL187, HL186). Revenue is generated through direct pharmaceutical sales in Korea and licensing/royalty agreements with global partners such as Immunovant and Daewoong Pharmaceutical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Phase 3 MG study: met primary endpoint of mean change from baseline in MG-ADL in ACHR population at 12 weeks (680mg: 5.6, 340mg: 4.7, placebo: 3.6)
+5 more records
Product overview1 text field

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative therapies across four key therapeutic areas: Ophthalmology, Immunology, Oncology, and Neurology. The company's pipeline centers on novel biologic drugs including tanfanercept (anti-TNF for dry eye disease), batoclimab and HL161ANS (anti-FcRn antibodies for autoimmune diseases), HL192 (Nurr1 activator for Parkinson's), and immuno-oncology candidates (HL187 anti-TIGIT, HL186 anti-TIM-3). The company also holds an exclusive license to Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. HanAll operates alongside established commercial products in endocrine, circulatory, and urologic therapeutic areas with over 50 years of operating history.

Product and service7 records
1Batoclimab (HL161)
CategoryAnti-FcRn antibody (immunology/autoimmune pipeline asset)
Description

A novel, fully human, subcutaneously administered antibody targeting the neonatal Fc receptor (FcRn), designed to selectively bind to FcRn to reduce levels of harmful IgG antibodies. Being developed for IgG-mediated autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Licensed to Immunovant for development and commercialization in the US and Europe.

2Tanfanercept (HL036)
CategoryTopical anti-TNF biologic (ophthalmology pipeline asset)
Description

A novel, topical, anti-inflammatory treatment targeting tumor necrosis factor (TNF) for dry eye disease (DED). It is a molecularly engineered tumor necrosis factor receptor 1 (TNFR1) fragment with strong affinity for TNF and resistance to degradation by proteinases. Co-developed with Daewoong Pharmaceutical.

3HL161ANS (IMVT-1402)
CategoryNext-generation anti-FcRn antibody (immunology/autoimmune pipeline asset)
Description

A next-generation anti-FcRn antibody designed to deliver maximum IgG reductions while minimizing interference with albumin recycling, demonstrating a potentially best-in-class profile with deep IgG reduction similar to batoclimab but with no or minimal changes in serum albumin and LDL-cholesterol level. Subcutaneous administration. Being advanced by Immunovant across multiple registrational studies.

4HL192 (ATH-399A)
CategoryNurr1 activator (neurology/Parkinson's disease pipeline asset)
Description

A Nurr1 activator developed as a potential disease-modifying therapy for Parkinson's disease. Nurr1 is a master regulator in dopaminergic neuron development and maintenance and an important component in anti-inflammatory functions. Co-developed with NurrOn Pharmaceuticals and Daewoong Pharmaceutical, in collaboration with Harvard Medical School.

5HL187
CategoryAnti-TIGIT monoclonal antibody (oncology pipeline asset)
Description

A monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.

6HL186
CategoryAnti-TIM-3 monoclonal antibody (oncology pipeline asset)
Description

A monoclonal antibody targeting TIM-3 (T cell Ig and mucin domain-3) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.

7Commercial pharmaceutical portfolio (probiotics, hair loss, urology)
CategoryCommercial pharmaceutical products (endocrine, circulatory, urologic therapeutic areas)
Description

Established commercial pharmaceutical products sold in Korea and other regional markets addressing endocrine, circulatory, and urologic therapeutic areas, including probiotics, hair loss treatments, and urology medications. These products generated 133 billion KRW in sales in 2025 and have been the foundation of the company for over 50 years.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-25
Description

Co-development partnership with Daewoong Pharmaceutical and NurrOn Pharmaceuticals for HL192 (ATH-399A), a Nurr1 activator for Parkinson's disease. Successfully completed Phase 1 first-in-human study demonstrating safety and tolerability in 76 healthy participants. NurrOn received $1.7 million grant from The Michael J. Fox Foundation for Parkinson's Research in support of the trial.

2Turn Biotechnologies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

Exclusive licensing agreement granting HanAll rights to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic diseases. Deal value can exceed $300 million USD for the initial product. Expands relationship from initial investment in 2022.

hanall.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Co-development agreement for tanfanercept (HL036) for dry eye disease. Daewoong and HanAll jointly conducting Phase 3 VELOS-4 study. Also co-development partner for HL192 (ATH-399A) for Parkinson's disease.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Galux, an AI-powered antibody drug design company, as part of HanAll's AI platform expansion for antibody design and R&D infrastructure development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

argenx is the leading FcRn antibody developer (Vyvgart/efgartigimod) and the most direct competitor to HanAll's batoclimab and HL161ANS franchise in myasthenia gravis, CIDP, and other IgG-mediated autoimmune diseases.

TypeDirect peer
Description

Immunovant is a Roivant subsidiary that licensed batoclimab from HanAll for US/Europe and is independently developing next-gen FcRn candidate IMVT-1402 (HL161ANS). Its registrational strategy and clinical readout cadence directly drive HanAll's milestone and royalty economics.

TypeDirect peer
Description

UCB developed Rystiggo (rozanolixizumab), a subcutaneous FcRn antibody approved for myasthenia gravis, making it a direct FcRn competitor to HanAll's pipeline assets and a relevant comp for commercial trajectory in the same indication.

TypeRegional player
Description

Celltrion is a major Korean biopharmaceutical company developing biosimilars and novel biologics, including autoimmune and ophthalmology assets. As a Korean-headquartered peer with similar listing profile and biologics manufacturing capabilities, it provides a direct regional comparable.

TypeRegional player
Description

Samsung Bioepis is a Korean biosimilars and biopharmaceutical company developing immunology and oncology biologics. Its Korean domicile, biologics platform, and pipeline overlap with HanAll's immunology focus make it a relevant regional comparable.

TypeRegional player
Description

Daewoong is a Korean pharmaceutical company and HanAll's co-development partner on tanfanercept (HL036), HL192 (ATH-399A), and immuno-oncology assets HL186/HL187. Comparable in therapeutic area focus (immunology, neurology, ophthalmology) and Korean listed-company profile.

TypeBroad incumbent
Description

AbbVie is a global immunology leader with Humira, Skyrizi, and Rinvoq across multiple autoimmune indications. As a broad incumbent in the same disease areas HanAll targets via FcRn antibodies, it shapes competitive and pricing dynamics for IgG-mediated disease therapies.

TypeBroad incumbent
Description

Regeneron is a leading antibody platform company with Eylea in ophthalmology and a strong immunology pipeline. Comparable to HanAll on antibody-based innovation, biologics manufacturing, and large commercial partnerships (e.g., Sanofi/Bayer).

TypeBroad incumbent
Description

Novartis has a substantial ophthalmology franchise (Xiidra, Beovu) directly relevant to HanAll's tanfanercept dry eye program, and a growing immunology pipeline. Its commercial reach and R&D scale make it a key incumbent competitor across HanAll's focus areas.

TypeRegional player
Description

Yuhan is a top Korean pharmaceutical company with a diversified established-product portfolio and pipeline in immunology, oncology, and chronic disease. Comparable to HanAll on Korean listed-company profile, commercial scale in Korea, and pipeline breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HanAll Biopharma

Biopharmaceuticalshanall.com

HanAll Biopharma (KRX: 009420.KS) is a Seoul-based, publicly listed biopharmaceutical company developing FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF (tanfanercept), a Nurr1 activator (HL192) and licensed epigenetic reprogramming technology, licensed globally via Immunovant, Daewoong, NurrOn and Turn Bio, alongside a Korean specialty pharma portfolio.

What HanAll Biopharma does

HanAll Biopharma Co., Ltd. (KRX: 009420.KS) is a Seoul-headquartered, publicly listed biopharmaceutical company founded in 1973 that develops innovative biologic medicines across ophthalmology, immunology, oncology, and neurology. Its pipeline is anchored by batoclimab (HL161) and the next-generation HL161ANS (IMVT-1402), both fully human subcutaneous antibodies targeting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG in autoimmune diseases including myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease; HL161ANS is licensed to Immunovant for the US and Europe and is designed to minimize albumin and LDL perturbation. Tanfanercept (HL036) is a molecularly engineered topical TNFR1 fragment for dry eye disease, currently in the Phase 3 VELOS-4 study with Daewoong Pharmaceutical. HL192 (ATH-399A) is a Nurr1 activator co-developed with Daewoong and NurrOn Pharmaceuticals as a potential disease-modifying therapy for Parkinson's disease, having completed a 76-participant Phase 1 first-in-human study in 2024. HanAll also holds an exclusive license to Turn Biotechnologies' Epigenetic Reprogramming of Aging (ERATM) mRNA technology for ophthalmic and otic indications, with potential deal value exceeding US$300 million for the initial product, and is co-developing immuno-oncology assets HL187 (anti-TIGIT) and HL186 (anti-TIM-3) with Daewoong.

The company's revenue model combines direct sales of an established Korean pharmaceutical portfolio in endocrine, circulatory, and urologic therapeutic areas (133 billion KRW in 2025, 13% YoY growth, three consecutive years of double-digit growth) with licensing, milestone, and co-development receipts from global partners including Immunovant, Daewoong, NurrOn, and Turn Biotechnologies. Distribution is via traditional pharmaceutical channels in Korea and through licensed partners internationally; the company maintains offices in Seoul, Rockville (MD, USA), Osaka (Japan), and Indonesia. Revenue economics are increasingly tied to clinical and regulatory milestones across the FcRn franchise and the maturing ophthalmology and neurology programs, offset by an active cost base — operating profit was -0.9 billion KRW in 2025 and net income -5.6 billion KRW versus +3.5 billion KRW in 2023, reflecting elevated SG&A and R&D investment (over 10% of annual revenue).

Customer concentration is bimodal: a distributed base of Korean wholesalers, hospitals, and pharmacies absorbs the legacy pharmaceutical volume, while a small set of global licensing partners — principally Immunovant for US/European FcRn rights and Daewoong for co-developed assets — governs the long-term value realization of the pipeline. This concentration was sharpened by the termination of the Harbour BioMed Greater China license in March 2025 and by Immunovant's April 2026 Phase 3 failure of batoclimab in thyroid eye disease, both of which crystallize near-term execution risk on the company's most strategic licensing relationship.

HanAll Biopharma firmographics

Firmographics
Name
HanAll Biopharma
Legal name
HanAll Biopharma Co., Ltd.
Website
https://hanall.com
Company type
Public
Founded year
1973
Operating status
Operating
Headcount range
11–50 employees
Short description
HanAll Biopharma (KRX: 009420.KS) is a Seoul-based, publicly listed biopharmaceutical company developing FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF (tanfanercept), a Nurr1 activator (HL192) and licensed epigenetic reprogramming technology, licensed globally via Immunovant, Daewoong, NurrOn and Turn Bio, alongside a Korean specialty pharma portfolio.
Ownership category
akta.pro rank

HanAll Biopharma industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Biopharmaceutical development
  • Anti-FcRn antibodies
  • Autoimmune disease therapeutics
  • Immuno-oncology pipeline
  • Topical ophthalmology drugs

Where HanAll Biopharma is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices6 records

Markets served

HanAll Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Sales of established pharmaceutical products including probiotics, hair loss treatments, and urology medications. Generated 133 billion KRW in pharmaceutical sales in 2025 with 13% year-over-year growth, marking three consecutive years of double-digit growth.
  2. Licensing and Milestone Payments: Revenue from licensing agreements including upfront payments, development milestones, and royalties from partners such as Immunovant for US/Europe and Harbour BioMed for China.
  3. Co-development and Collaboration Revenue: Revenue from co-development partnerships including milestone achievements from collaborations with Daewoong Pharmaceutical, NurrOn Pharmaceuticals, and other partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

HanAll Biopharma product offering

Product offering

Core offering

HanAll Biopharma is a global biopharmaceutical company that develops, manufactures, and commercializes innovative biologic therapies across four therapeutic areas — Ophthalmology, Immunology, Oncology, and Neurology. The company's commercial portfolio spans established prescription drugs (probiotics, hair loss, and urology medications) in Korean and Asian markets, while its R&D pipeline includes anti-FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF for dry eye disease (tanfanercept), a Nurr1 activator for Parkinson's (HL192), and immuno-oncology candidates (HL187, HL186). Revenue is generated through direct pharmaceutical sales in Korea and licensing/royalty agreements with global partners such as Immunovant and Daewoong Pharmaceutical.

Product overview

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative therapies across four key therapeutic areas: Ophthalmology, Immunology, Oncology, and Neurology. The company's pipeline centers on novel biologic drugs including tanfanercept (anti-TNF for dry eye disease), batoclimab and HL161ANS (anti-FcRn antibodies for autoimmune diseases), HL192 (Nurr1 activator for Parkinson's), and immuno-oncology candidates (HL187 anti-TIGIT, HL186 anti-TIM-3). The company also holds an exclusive license to Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. HanAll operates alongside established commercial products in endocrine, circulatory, and urologic therapeutic areas with over 50 years of operating history.

Differentiator

Problem solved

Functional benefit

Products and services

  • Batoclimab (HL161) A novel, fully human, subcutaneously administered antibody targeting the neonatal Fc receptor (FcRn), designed to selectively bind to FcRn to reduce levels of harmful IgG antibodies. Being developed for IgG-mediated autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Licensed to Immunovant for development and commercialization in the US and Europe.
  • Tanfanercept (HL036) A novel, topical, anti-inflammatory treatment targeting tumor necrosis factor (TNF) for dry eye disease (DED). It is a molecularly engineered tumor necrosis factor receptor 1 (TNFR1) fragment with strong affinity for TNF and resistance to degradation by proteinases. Co-developed with Daewoong Pharmaceutical.
  • HL161ANS (IMVT-1402) A next-generation anti-FcRn antibody designed to deliver maximum IgG reductions while minimizing interference with albumin recycling, demonstrating a potentially best-in-class profile with deep IgG reduction similar to batoclimab but with no or minimal changes in serum albumin and LDL-cholesterol level. Subcutaneous administration. Being advanced by Immunovant across multiple registrational studies.
  • HL192 (ATH-399A) A Nurr1 activator developed as a potential disease-modifying therapy for Parkinson's disease. Nurr1 is a master regulator in dopaminergic neuron development and maintenance and an important component in anti-inflammatory functions. Co-developed with NurrOn Pharmaceuticals and Daewoong Pharmaceutical, in collaboration with Harvard Medical School.
  • HL187 A monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.
  • HL186 A monoclonal antibody targeting TIM-3 (T cell Ig and mucin domain-3) being developed in collaboration with Daewoong Pharmaceutical as a potential immuno-oncology treatment.
  • Commercial pharmaceutical portfolio (probiotics, hair loss, urology) Established commercial pharmaceutical products sold in Korea and other regional markets addressing endocrine, circulatory, and urologic therapeutic areas, including probiotics, hair loss treatments, and urology medications. These products generated 133 billion KRW in sales in 2025 and have been the foundation of the company for over 50 years.

Quantifiable outcome

  • Phase 3 MG study: met primary endpoint of mean change from baseline in MG-ADL in ACHR population at 12 weeks (680mg: 5.6, 340mg: 4.7, placebo: 3.6)
  • +5 more outcomes

Companies that use HanAll Biopharma

Customer profile

Segments4 records

Ideal customer profiles1 record

HanAll Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

HanAll Biopharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • NurrOn PharmaceuticalscoreStrategic or Co-development Partner · 25 November 2024Co-development partnership with Daewoong Pharmaceutical and NurrOn Pharmaceuticals for HL192 (ATH-399A), a Nurr1 activator for Parkinson's disease. Successfully completed Phase 1 first-in-human study demonstrating safety and tolerability in 76 healthy participants. NurrOn received $1.7 million grant from The Michael J. Fox Foundation for Parkinson's Research in support of the trial.
  • Turn BiotechnologiescoreStrategic or Co-development Partner · 28 May 2024Exclusive licensing agreement granting HanAll rights to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic diseases. Deal value can exceed $300 million USD for the initial product. Expands relationship from initial investment in 2022.
  • Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 7 May 2024Co-development agreement for tanfanercept (HL036) for dry eye disease. Daewoong and HanAll jointly conducting Phase 3 VELOS-4 study. Also co-development partner for HL192 (ATH-399A) for Parkinson's disease.
  • GaluxminorStrategic or Co-development PartnerCollaboration with Galux, an AI-powered antibody drug design company, as part of HanAll's AI platform expansion for antibody design and R&D infrastructure development.

Scale indicators14 records

Recent moves9 records

Expansion highlights5 records

HanAll Biopharma competitors and assessment

Company assessment

Direct peers

  • argenx: argenx is the leading FcRn antibody developer (Vyvgart/efgartigimod) and the most direct competitor to HanAll's batoclimab and HL161ANS franchise in myasthenia gravis, CIDP, and other IgG-mediated autoimmune diseases.
  • Immunovant: Immunovant is a Roivant subsidiary that licensed batoclimab from HanAll for US/Europe and is independently developing next-gen FcRn candidate IMVT-1402 (HL161ANS). Its registrational strategy and clinical readout cadence directly drive HanAll's milestone and royalty economics.
  • UCB: UCB developed Rystiggo (rozanolixizumab), a subcutaneous FcRn antibody approved for myasthenia gravis, making it a direct FcRn competitor to HanAll's pipeline assets and a relevant comp for commercial trajectory in the same indication.

Regional players

  • Celltrion: Celltrion is a major Korean biopharmaceutical company developing biosimilars and novel biologics, including autoimmune and ophthalmology assets. As a Korean-headquartered peer with similar listing profile and biologics manufacturing capabilities, it provides a direct regional comparable.
  • Samsung Bioepis: Samsung Bioepis is a Korean biosimilars and biopharmaceutical company developing immunology and oncology biologics. Its Korean domicile, biologics platform, and pipeline overlap with HanAll's immunology focus make it a relevant regional comparable.
  • Daewoong Pharmaceutical: Daewoong is a Korean pharmaceutical company and HanAll's co-development partner on tanfanercept (HL036), HL192 (ATH-399A), and immuno-oncology assets HL186/HL187. Comparable in therapeutic area focus (immunology, neurology, ophthalmology) and Korean listed-company profile.
  • Yuhan Corporation: Yuhan is a top Korean pharmaceutical company with a diversified established-product portfolio and pipeline in immunology, oncology, and chronic disease. Comparable to HanAll on Korean listed-company profile, commercial scale in Korea, and pipeline breadth.

Broad incumbents

  • AbbVie: AbbVie is a global immunology leader with Humira, Skyrizi, and Rinvoq across multiple autoimmune indications. As a broad incumbent in the same disease areas HanAll targets via FcRn antibodies, it shapes competitive and pricing dynamics for IgG-mediated disease therapies.
  • Regeneron: Regeneron is a leading antibody platform company with Eylea in ophthalmology and a strong immunology pipeline. Comparable to HanAll on antibody-based innovation, biologics manufacturing, and large commercial partnerships (e.g., Sanofi/Bayer).
  • Novartis: Novartis has a substantial ophthalmology franchise (Xiidra, Beovu) directly relevant to HanAll's tanfanercept dry eye program, and a growing immunology pipeline. Its commercial reach and R&D scale make it a key incumbent competitor across HanAll's focus areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

HanAll Biopharma social profiles

Digital presence

HanAll Biopharma compliance and trust

Trust signal

Compliance2 records

HanAll Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HanAll Biopharma leadership team

Management profile

Number of profiles

Profiles6 records

HanAll Biopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HanAll Biopharma M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HanAll Biopharma

What does HanAll Biopharma do?

HanAll Biopharma is a global biopharmaceutical company that develops, manufactures, and commercializes innovative biologic therapies across four therapeutic areas — Ophthalmology, Immunology, Oncology, and Neurology. The company's commercial portfolio spans established prescription drugs (probiotics, hair loss, and urology medications) in Korean and Asian markets, while its R&D pipeline includes anti-FcRn antibodies (batoclimab, HL161ANS), a topical anti-TNF for dry eye disease (tanfanercept), a Nurr1 activator for Parkinson's (HL192), and immuno-oncology candidates (HL187, HL186). Revenue is generated through direct pharmaceutical sales in Korea and licensing/royalty agreements with global partners such as Immunovant and Daewoong Pharmaceutical.

Is HanAll Biopharma a public or private company?

HanAll Biopharma is a public company. It is classified as public and is currently operating.

When was HanAll Biopharma founded?

HanAll Biopharma was founded in 1973. It employs 11 to 50 people.

Where is HanAll Biopharma based?

HanAll Biopharma is headquartered in Seoul, South Korea, in the Asia region.

How does HanAll Biopharma make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments and co-development and Collaboration Revenue.

Who are HanAll Biopharma's main competitors?

Direct peers on record are argenx, Immunovant and UCB. Regional players are Celltrion, Samsung Bioepis, Daewoong Pharmaceutical and Yuhan Corporation. Broad incumbents are AbbVie, Regeneron and Novartis.

Does HanAll Biopharma have an API?

No public API is recorded for HanAll Biopharma.

What industry is HanAll Biopharma in?

HanAll Biopharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinesskoreaHanAll Biopharma has obtained product approval for batoclimab in China.China's NMPA approved batoclimab subcutaneous injection for adult generalized myasthenia gravis patients. Phase 3 data showed 58.2% of treated patients improved by 3+ points on MG-ADL versus 31.3% placebo, with rapid symptom relief. Harbor BioMed will commercialize the drug, with milestone and royalty payments to HanAll Biopharma.GlobeNewswireRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Roivant Sciences announced that its subsidiary Priovant has enrolled first subjects in a seamless Phase 2b/3 registrational trial of brepocitinib for lichen planopilaris (LPP) in March 2026, marking the fourth indication in the drug's late-stage development program. Simultaneously, Immunovant reported that its two Phase 3 studies of batoclimab for thyroid eye disease (TED) failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24. The FDA has granted Priority Review to brepocitinib's NDA for dermatomyositis with a PDUFA target action date in Q3 2026, and Immunovant intends to review future plans for batoclimab with its partner HanAll Biopharma.GlobeNewswireRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Roivant announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), enrolling first subjects in March 2026, marking the fourth indication in the drug's late-stage development pipeline alongside dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. Separately, Immunovant's Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24, leading Immunovant to plan future development discussions with partner HanAll Biopharma while shifting focus to IMVT-1402. The batoclimab studies showed greater proptosis improvement during the high-dose period versus low-dose period, supporting the benefit of deeper IgG suppression.LinkedInHanAll BiopharmaHanAll Biopharma, a global biopharmaceutical company, operates a portfolio of pharmaceutical products across endocrine, circulatory, and urologic diseases. Its lead pipeline asset HL161, an anti-FcRn antibody, is in Phase 3 and Phase 2 trials for autoimmune diseases, while HL036, a TNF-alpha inhibitor, is in Phase 3 studies for dry eye disease.ChosunbizHANall Biopharma posts 117.6 billion won sales as R&D investment drives drug developmentHANALL BIOPHARMA reported first-to-third-quarter sales of 117.6 billion won, up 14.7% year-over-year, while posting operating profit despite R&D spending rising to 36.4 billion won (26.3% of sales). The company plans to reinvest revenue into new drug development, including autoimmune disease treatments and a dry eye candidate.YahooHanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye DiseaseHanAll Biopharma announced that Batoclimab received Orphan Drug Designation from Japan's MHLW for active Thyroid Eye Disease, affecting about 35,000 patients. The subcutaneous formulation aims to enable at-home administration, and a Phase 3 study is ongoing with top-line results expected in H2 2025.PR NewswireHanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye DiseaseHanAll Biopharma announced that Batoclimab received Orphan Drug Designation from Japan's MHLW for active Thyroid Eye Disease, affecting about 35,000 patients. The subcutaneous formulation aims for at-home administration, and a Phase 3 study is ongoing with top-line results expected in H2 2025.MorningstarHanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye DiseaseHanAll Biopharma announced that Batoclimab received Orphan Drug Designation from Japan's MHLW for active Thyroid Eye Disease. The subcutaneous formulation aims to enable at-home administration, with a Phase 3 study ongoing and top-line results expected in H2 2025.Business & FinancialHanall Biopharma Announces Orphan Drug Designation For Batoclimab In Japan For Active Thyroid Eye DiseaseHanAll Biopharma announced that Batoclimab received Orphan Drug Designation from Japan's MHLW for active Thyroid Eye Disease. The subcutaneous formulation is expected to allow at-home administration, with a Phase 3 study ongoing and top-line results expected in H2 2025.PR NewswireHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's DiseaseHanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals completed a Phase 1 study of HL192 (ATH-399A) for Parkinson's disease, enrolling 76 healthy participants. The study met safety and tolerability endpoints with no serious adverse events, and PK data support once-daily dosing. The companies plan to initiate the next clinical trial in Parkinson's patients.